2021
DOI: 10.1111/ene.14999
|View full text |Cite
|
Sign up to set email alerts
|

Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer’s disease

Abstract: Background: Alzheimer's disease (AD) is characterized by a heterogeneous course.Predicting a fast rather than a slow decline over time is crucial to both provide a reliable prognosis and elaborate stricter enrolment criteria in clinical trials. Here we searched for independent predictors of cognitive decline rate to assess the risk of fast disease progression already at baseline. Methods: Fifty-three subjects with an "in-vivo biomarker confirmed" diagnosis of AD were included. Neuropsychological assessment, pl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 45 publications
0
6
0
Order By: Relevance
“…Moreover, plasma NfL levels had suitable sensitivity to discriminate between MCI-AD and dementia-AD. Additionally, plasma NfL levels correlated with worse neuropsychological performance (lower MMSE score and higher CDR score), constituting a potential neurodegeneration and dementia biomarker, as suggested in another study [ 27 ]. This finding could be helpful in progression studies.…”
Section: Discussionmentioning
confidence: 73%
See 1 more Smart Citation
“…Moreover, plasma NfL levels had suitable sensitivity to discriminate between MCI-AD and dementia-AD. Additionally, plasma NfL levels correlated with worse neuropsychological performance (lower MMSE score and higher CDR score), constituting a potential neurodegeneration and dementia biomarker, as suggested in another study [ 27 ]. This finding could be helpful in progression studies.…”
Section: Discussionmentioning
confidence: 73%
“…In general, individual plasma biomarkers have shown good accuracy for AD diagnosis, which could be improved by the simultaneous combination of some plasma biomarkers [ 22 , 23 , 24 , 25 ]. The neurofilament light chain (NfL) is another molecule that has been analyzed in the context of AD as a progression biomarker [ 26 ] or predictor for dementia, even more helpful in other pathologies, such as FTLD [ 27 , 28 ]. Different works pointed out the potential use of these biomarkers mentioned, which could change the clinical guides in the following years, with earlier and higher accessible diagnosis [ 29 , 30 , 31 , 32 ].…”
Section: Introductionmentioning
confidence: 99%
“…The role of NfL as a potential biomarker for AD has been extensively reviewed and recent meta-analysis regarding its association with AD can be found elsewhere (Olsson et al, 2016;Khalil et al, 2018;Bridel et al, 2019;Jin et al, 2019). Recent studies further demonstrated plasma NfL levels or together with cognitive testing as predictors of fast progression (Santangelo et al, 2021) and future declines in cognition and function in AD (Li et al, 2021). Hyperphosphorylation of tau neurofibrillary tangles is one of the hallmarks in AD.…”
Section: Alzheimer's Diseasementioning
confidence: 99%
“…In AD PTMs lead to a four to eightfold increase of phosphorylation of NfH and NfM compared to controls (Rudrabhatla et al, 2011). In AD it has been shown that elevated NfL levels are associated with disease progression (Moscoso et al, 2021; Santangelo et al, 2021). In section 7 the relevance of NfL breakdown products, notably in the 10 kDa range (Brureau et al, 2017).…”
Section: Diseasesmentioning
confidence: 99%